Table 1 Baseline clinical characteristics of the two groups
From: Association between increased serum alkaline phosphatase and the coronary slow flow phenomenon
CSFP group (n = 64) | Control group (n = 50) | P value | |
|---|---|---|---|
Age (years) | 58.6 ± 7.9 | 57.4 ± 8.4 | 0.25 |
Males, n(%) | 29(45.3) | 24(48.0) | 0.85 |
BMI, (kg/m2) | 24.7 ± 3.2 | 25.2 ± 5.3 | 0.59 |
Current smoker, n(%) | 9(14.1) | 6(12.0) | 0.79 |
Dyslipidemia, n (%) | 10(15.6) | 6(12.0) | 0.79 |
Diabetes mellitus, n(%) | 9(14.1) | 5(10.0) | 0.58 |
systolic blood pressure, (mmHg) | 123.7 ± 15.0 | 125.4 ± 13.2 | 0.62 |
Diastolic bloodpressure, (mmHg) | 77.7 ± 9.4 | 81.7 ± 10.9 | 0.11 |
Medications | |||
Aspirin, n(%) | 40(62.5) | 32(64.0) | 0.29 |
Statin, n(%) | 38(59.4) | 32(64.0) | 0.70 |
ACEI/ARB, n(%) | 8(12.5) | 9(18.0) | 0.44 |
CCB, n(%) | 6(9.4) | 7(14.0) | 0.56 |
Nitrates, n(%) | 36(6.3) | 30(60.0) | 0.71 |